Abstract:A novel approach is developed for synergistic chemoimmunotherapy by utilizing dual‐responsive covalent organic frameworks (COFs) to co‐deliver doxorubicin (DOX) and programmed cell death ligand‐1 (PD‐L1) siRNA (siPD‐L1), which triggers immunogenic cell death (ICD) and suppresses PD‐L1 expression in tumor cells, thereby resulting in synergistically improved antitumor efficacy and antimetastatic effect. Chemoimmunotherapy, which integrates chemotherapeutic drugs with immune modulators, has emerged as a promising approach to enhance the generally lackluster clinical outcomes of immunotherapy. Nevertheless, a significant challenge lies in orchestrating multiple events associated with diverse mechanisms that activate antitumor immune responses. Here, a novel approach utilizing dual‐responsive covalent organic frameworks (COFs) co‐encapsulating doxorubicin (DOX) and programmed cell death ligand‐1 (PD‐L1) siRNA (siPD‐L1), termed RDAP, is presented for synergistic chemoimmunotherapy. In this system, COFs modified with poly‐L‐lysine (PLL) can adsorb DOX within their porous structure and bind siPD‐L1 onto their surface via electrostatic interactions. The resulting RDAP formulation can escape from lysosome via the "proton sponge effect" and undergo rupture upon exposure to azoreductase, leading to the efficient release of DOX and siPD‐L1 into the cytoplasm of 4T1 cells. The RDAP, harboring dual therapeutic agents, can effectively eliminate tumor cells and trigger significant immunogenic cell death (ICD) through DOX. Additionally, it concomitantly suppresses PD‐L1 expression in tumor cells, thereby significantly enhancing the antitumor immune response and resulting in synergistically improved antitumor efficacy. In mouse models, RDAP demonstrated exceptional efficacy in eliminating both primary and distant tumors, along with a pronounced antimetastatic effect against 4T1 murine breast‐to‐lung metastasis.

A Dual-Locked Cyclopeptide-Sirna Conjugate for Tumor-Specific Gene Silencing.

A Dual Targeting Dendrimer-Mediated Sirna Delivery System for Effective Gene Silencing in Cancer Therapy.

Reductive Nanocomplex Encapsulation of Crgd-Sirna Conjugates for Enhanced Targeting to Cancer Cells.

Bioreducible, Arginine-Rich Polydisulfide-Based Sirna Nanocomplexes with Excellent Tumor Penetration for Efficient Gene Silencing.

Delivery Pathway Regulation of 3′,3″-Bis-peptide-sirna Conjugate Via Nanocarrier Architecture Engineering

Phenylboronic Acid-Functionalized Polyamidoamine-Mediated Bcl-2 Sirna Delivery for Inhibiting the Cell Proliferation.

A DNA dual lock-and-key strategy for cell-subtype-specific siRNA delivery

Cyclodextrin and Polyethylenimine Functionalized Mesoporous Silica Nanoparticles for Delivery of Sirna Cancer Therapeutics.

Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers

Copackaging Doxorubicin and PD‐L1 siRNA in Dual‐Responsive Covalent Organic Frameworks for Synergistic Cancer Chemoimmunotherapy

A tumor-activatable peptide supramolecular nanoplatform for the delivery of dual-gene targeted siRNAs for drug-resistant cancer treatment

A Nanoconfined Loading Strategy for Highly Efficient Sirna Delivery and Cancer Therapy

Intracellular Co-delivery of native antibody and siRNA for combination therapy by using biodegradable silica nanocapsules.

Dual-Action Protein-siRNA Conjugates for Targeted Disruption of CD47-Signal Regulatory Protein α Axis in Cancer Therapy.

Investigation of a Dual Sirna/chemotherapy Delivery System for Breast Cancer Therapy

Redox-Responsive Polymeric RNAi Based on Multivalent Conjugation of siRNA for Improved Intracellular Delivery.

Tumor-Targeted In Vivo Gene Silencing Via Systemic Delivery Of Crgd-Conjugated Sirna

Smart Nanoparticles Assembled by Endogenous Molecules for Sirna Delivery and Cancer Therapy Via CD44 and EGFR Dual-Targeting

Erythrocyte Membrane Camouflaged Sirna/chemodrug Nanoassemblies for Cancer Combination Therapy.

Tumor-Targeting Peptide for Redox-Responsive Pt Prodrug and Gene Codelivery and Synergistic Cancer Chemotherapy.

Tumor-Targeted Codelivery of CpG and siRNA by a Dual-Ligand-Functionalized Curdlan Nanoparticle